Ross van de Wetering

6PUBLICATIONS
11CO-AUTHORS
Molecular medicineMolecular targetsRegenerative medicine (incl. stem cells)Metabolic medicineToxicology (incl. clinical toxicology)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Sep 02, 2025
Role of β-Arrestin 2 in the antinociceptive and side effect profile of morphine and the novel mu opioid receptor agonists, kurkinorin and kurkinol.

Ross van de Wetering, Amy F Alder, Andrew Biggerstaff

|Feb 13, 2025
Effects of Biased Analogues of the Kappa Opioid Receptor Agonist, U50,488, in Preclinical Models of Pain and Side Effects.

Ross van de Wetering, Loan Y Vu, Lindsay D Kornberger

|Jun 20, 2024
Nalfurafine promotes myelination in vitro and facilitates recovery from cuprizone + rapamycin-induced demyelination in mice.

Ross van de Wetering, Rabia Bibi, Andy Biggerstaff

|Aug 02, 2023
Behavioral metabolomics: how behavioral data can guide metabolomics research on neuropsychiatric disorders.

Ross van de Wetering, Jan A Vorster, Sophie Geyrhofer

|Jun 28, 2023
The Kappa Opioid Receptor Agonist 16-Bromo Salvinorin A Has Anti-Cocaine Effects without Significant Effects on Locomotion, Food Reward, Learning and Memory, or Anxiety and Depressive-like Behaviors.

Ross van de Wetering, Amy Ewald, Susan Welsh

|Aug 03, 2019
Regional changes in ∆FosB expression in rat brain following MDMA self-administration predict increased sensitivity to effects of locally infused MDMA.

Ross van de Wetering, Susan Schenk

Pageof 1

Frequent Collaborators

4 joint publications

Thomas E Prisinzano

4 joint publications

Bronwyn M Kivell

2 joint publications

Susan Schenk

1 joint publications

Samuel E Williamson